Execution Without Direction: The Hidden Risk In Outsourced Clinical Trials

As more clinical trials are outsourced, a widening gap has formed between what sponsors expect and how CROs deliver. Smaller biotech companies, in particular, often depend heavily on external vendors to advance their programs—frequently without the internal clinical operations structure needed to guide strategy, maintain oversight, and ensure alignment.

Meanwhile, vendor teams — especially CRAs — are often overextended, focused on completing discrete tasks without full visibility into the broader study objectives. This dynamic creates a growing disconnect: between sponsors and CROs, CRAs and sites, and even between study protocols and real-world execution. The consequences can include inefficiencies, increased risk, and strained relationships with sites, all of which can undermine trial success.

In this webinar, industry experts unpack the underlying causes of these challenges and consider whether clinical oversight monitors represent a necessary evolution or simply an additional layer of complexity. Drawing on real-world examples and practical insights, the discussion highlights ways to better align stakeholders, strengthen execution, and bridge operational gaps.